Fukui R, Watanabe T, Morimoto K, Fujimoto Y, et al. Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al. Breast Cancer 2024;31:536-538.
PMID: 38433180